Along similar lines, another class of compounds, referred to as “mitotic drivers”, triggering premature mitotic exit by targeting key mitotic kinases such as MPS1 or Aurora B, forcing chromosome missegregation or mitotic slippage with cytokinesis failure, respectively, are under development for cancer treatment 2, 3. This evidence concerns the gene AURKB and cancer.